Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Statement re NAV and Interim Dividend

3 Aug 2021 11:31

RNS Number : 4204H
Maven Income and Growth VCT 3 PLC
03 August 2021
 

Maven Income and Growth VCT 3 PLC

 

Unaudited Net Asset Value (NAV) and Interim Dividend

 

The Directors of Maven Income and Growth VCT 3 PLC (the Company) confirm that the unaudited NAV of the Company as at 31 May 2021 was 60.76p per Ordinary Share. This is an increase of 2.51p since the previously announced NAV of 58.25p as at 28 February 2021, and represents an uplift of 4.31%. The NAV increase is largely attributable to several profitable realisations, all of which completed at valuations ahead of carrying value, alongside uplifts to the valuations of companies that are delivering growth in recurring revenues. In addition, on 22 July 2021, GEN InCode was successfully floated on AIM, raising £17 million and achieving a market capitalisation at listing of £42 million.

 

The Board is pleased to declare that an interim dividend of 1.25p per Ordinary Share, in respect of the year ending 30 November 2021, will be paid on 10 September 2021 to Shareholders on the register at close of business on 13 August 2021. Since the Company's launch, and after receipt of this latest dividend, 90.42p per share will have been distributed in tax-free dividends. It should be noted that the effect of paying a dividend is to reduce the NAV of the Company by the total cost of the distribution.

The Company has in place a Dividend Investment Scheme (DIS) through which Shareholders may elect to have their dividend payments used to apply for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax reliefs applicable for the tax year in which they are allotted. Terms & conditions of the scheme, together with a mandate form, are available from the Company's website at: www.mavencp.com/migvct3.

Shareholders who have not previously applied to participate in the DIS and who wish to do so in respect of the dividend payable on 10 September 2021, should ensure that a mandate form, or CREST instruction if appropriate, is submitted prior to the dividend election date of 27 August 2021.

 

Further to the information disclosed above, the Directors confirm that they are satisfied that all inside information (as defined by Article 7 of the Market Abuse Regulation (596/2014/EU)) that the Directors and the Company may have in their possession relating to the Company during the 30 day closed period leading up to the announcement of its interim results for the six months ended 31 May 2021 has been or will be notified to a regulatory information service.

 

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Secretary

3 August 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRBGGDIRDGDGBX
Date   Source Headline
27th Mar 20251:06 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:53 pmRNSUnaudited Net Asset Value
18th Mar 20253:37 pmRNSAnnual Financial Report
28th Feb 20254:32 pmRNSTransaction in Own Shares
27th Feb 20251:54 pmRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:17 amRNSDirector/PDMR Shareholding
19th Feb 202510:14 amRNSDirector/PDMR Shareholding
19th Feb 202510:06 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
18th Dec 20249:35 amRNSIssue of Equity
13th Dec 20242:42 pmRNSNet Asset Value(s)
14th Nov 20242:55 pmRNSResult of General Meeting
25th Oct 20243:49 pmRNSTransaction in Own Shares
27th Sep 20244:31 pmRNSPublication of a Prospectus
6th Sep 202410:25 amRNSDirector/PDMR Shareholding
6th Sep 202410:01 amRNSIssue of Equity
5th Sep 20242:26 pmRNSStatement re Dividend Investment Scheme
5th Sep 20241:40 pmRNSUnaudited Net Asset Value
18th Jul 20245:27 pmRNSHalf-year Report
10th Jul 20245:08 pmRNSTransaction in Own Shares
8th Jul 20244:07 pmRNSStatement re NAV and Interim Dividend
18th Jun 202411:53 amRNSStatement re Intended Offers for Subscription
10th May 20244:11 pmRNSTransaction in Own Shares
3rd May 20249:35 amRNSDirector/PDMR Shareholding
3rd May 20249:33 amRNSIssue of Equity
2nd May 20241:31 pmRNSResult of AGM
1st May 202410:06 amRNSDirector/PDMR Shareholding
1st May 202410:03 amRNSIssue of Equity
26th Apr 20242:40 pmRNSNet Asset Value - Dividend Investment Scheme
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:37 pmRNSIssue of Equity
28th Mar 202410:16 amRNSStatement re Offer for Subscription
27th Mar 202410:36 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:46 pmRNSUnaudited Net Asset Value
15th Mar 20245:18 pmRNSAnnual Financial Report
21st Feb 20244:24 pmRNSTransaction in Own Shares
8th Feb 202410:30 amRNSDirector/PDMR Shareholding
8th Feb 202410:28 amRNSDirector/PDMR Shareholding
8th Feb 202410:15 amRNSIssue of Equity
6th Feb 202411:07 amRNSDividend Declaration
19th Dec 20233:25 pmRNSIssue of Equity
18th Dec 20235:17 pmRNSUnaudited Net Asset Value
5th Dec 202311:42 amRNSDirectorate Change
9th Nov 20233:47 pmRNSResult of General Meeting
8th Nov 20234:01 pmRNSTransaction in Own Shares
7th Nov 20234:47 pmRNSTransaction in Own Shares
19th Oct 20234:15 pmRNSNet Asset Value
13th Oct 20234:56 pmRNSPublication of a Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.